Vitality Watch

Dossier pubmed preclinical 29-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.

Key claim: A long-term human skin explant platform preserved native architecture and molecular programs for up to 4 weeks and showed that senolytic-associated treatment reduced SASP factors in aged tissue while tofacitinib suppressed IL-17/IL-22-driven chronic inflammation.

Abstract

Chronic inflammation drives tissue dysfunction and aging, yet the dynamic interplay between persistent inflammatory signaling and structural deterioration remains difficult to study in human-relevant systems. Here, an advanced long-term human skin platform is presented that preserves native tissue architecture and epidermal, stromal, and immune-associated molecular programs for up to 4 weeks. Time-course RNA sequencing of 199 tissue samples from 20 donors revealed an early culture adaptation phase followed by stabilization of tissue-associated transcriptional programs. Using this system, sustained IL-17/IL-22 stimulation over 3 weeks induced chronic inflammatory transcriptional programs, progressive histopathological changes, and persistent secretion of IL-8, MCP-1, S100A8/A9, and MMP-1, which was broadly suppressed by the Janus kinase inhibitor tofacitinib. In aged donor tissue, prolonged senolytic-associated treatment attenuated inflammatory and remodeling pathways and reduced senescence-associated secretory factors, including IL-6 and MMP-1, with significant treatment-associated effects evident at Week 3 but not Week 1. Finally, ultraviolet B exposure triggered coordinated stress and inflammatory responses that were mitigated using topical sunscreen, demonstrating compatibility with environmental stress modeling and topical intervention. Together, these findings establish a versatile human skin platform for modeling chronic inflammation, aging-associated tissue remodeling, and environmental stress, providing a translational framework for investigating skin tissue dysfunction and evaluating therapeutic interventions.

Why this matters

Human skin explants maintained for weeks fill a persistent gap between murine aging models and clinical trials by letting senolytic and anti-cytokine effects be read on native aged human tissue architecture. The platform concurrently captures SASP reduction and IL-17/IL-22 suppression, aligning the senescence and inflammaging arms of skin aging on a single preclinical substrate. It is a translational-methods extension, not a new mechanism or human efficacy result.

Source

Link

Briefing card

Long-Term Human Skin Platform for Modeling Chronic Inflammation, Environmental Stress, and Therapeutic Intervention.
Stage: preclinical · pubmed · 29-sep-2026

If you follow senolytic or JAK-inhibitor skin-aging claims, this preclinical platform tests them in long-lived human skin tissue — it does not show benefit in people.

A long-term human skin explant platform preserved native architecture and molecular programs for up to 4 weeks and showed that senolytic-associated treatment reduced SASP factors in aged tissue while tofacitinib suppressed IL-17/IL-22-driven chronic inflammation.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1002/advs.78035

build build 880 · 2bcef25 · 2026-11-18